RESUMEN
SUMMARY: Failure to intubate and cross esophageal tumors by endosonography is reported in as many as 30% of cases and is thought to be associated with an especially poor prognosis. The aim of this study was to audit the above in a large consecutive case series of Endoscopic Ultrasound (EUS) examinations for esophageal cancer performed in a regional specialist cancer network with particular reference to outcome. A consecutive series of 411 patients underwent EUS examination by a specialist radiologist over a period of 9 years. Forty (10%) of patients required dilation, and there was total failure to cross the tumor in 12 patients (2.9%). Failure to traverse the primary tumor was associated with a diagnosis of squamous cell cancer (8 of 12 patients, 66%, rho = -0.182, P = 0.011). Limited staging information was obtained in 7 of these patients, which altered the computed tomography stage in 5 patients (71%, 3 upstaged, 2 downstaged). Six patients received definitive chemoradiotherapy, two patients surgery and four patients palliative chemotherapy. The median and 5-year survival in patients whose tumors were not crossed was 10 months and 28%, respectively, compared with 24 months and 24%, respectively in patients whose tumors were fully assessed. Failure to cross esophageal tumors in practice was far less common than the literature suggests, and esophageal tumor luminal stenosis should no longer be considered a limitation of endosonography.
Asunto(s)
Carcinoma de Células Escamosas/diagnóstico por imagen , Cateterismo/métodos , Endosonografía/métodos , Neoplasias Esofágicas/diagnóstico por imagen , Estenosis Esofágica/patología , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma de Células Escamosas/mortalidad , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/terapia , Quimioterapia Adyuvante , Terapia Combinada , Neoplasias Esofágicas/mortalidad , Neoplasias Esofágicas/patología , Neoplasias Esofágicas/terapia , Estenosis Esofágica/diagnóstico por imagen , Estenosis Esofágica/mortalidad , Estenosis Esofágica/terapia , Esofagectomía/métodos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Invasividad Neoplásica/patología , Probabilidad , Pronóstico , Radioterapia Adyuvante , Valores de Referencia , Medición de Riesgo , Análisis de Supervivencia , Carga TumoralRESUMEN
The kinetics of isosorbide 5-mononitrate (5-ISMN) were studied in 12 healthy subjects after intravenous infusion and oral doses of 20 mg. Kinetic parameters calculated by model-independent methods or by assumption of a one-compartment open model were in good agreement. Mean (+/- SD) systemic clearance of 5-ISMN was 127 +/- 21 ml/min, volume of distribution was 48.5 +/- 6.1 l, t 1/2 was 4.4 +/- 0.5 hr, and mean residence time was 6.2 +/- 0.7 hr. At the end of intravenous infusion of 5-ISMN at a rate of 8 mg/hr for 2.5 hr, mean plasma drug concentrations reached 356 +/- 39 ng/ml. Oral doses of 5-ISMN were essentially completely absorbed (93% +/- 13% systemic availability), and mean peak plasma drug concentrations of 388 +/- 70 ng/ml occurred at 0.83 +/- 0.46 hr. Mean absorption t 1/2 was 19 +/- 12 min. Unlike other vasodilator organic nitrates in clinical use, 5-ISMN is notable for its relatively long t 1/2, essentially complete oral absorption, lack of active metabolites, and low intersubject variability in kinetics.
Asunto(s)
Dinitrato de Isosorbide/análogos & derivados , Absorción , Administración Oral , Adulto , Disponibilidad Biológica , Humanos , Infusiones Parenterales , Dinitrato de Isosorbide/administración & dosificación , Dinitrato de Isosorbide/metabolismo , Cinética , Masculino , Distribución AleatoriaRESUMEN
Ro 11-2465, a cyanide derivative of imipramine with serotonin uptake inhibitory properties, was investigated in six healthy volunteers for its effect on serotonin concentration in blood platelets. The initial dose was 1 mg daily, the maximum dose of 3 mg being reached on day 3 and maintained for 7 days. A significant decrease in the platelet serotonin concentration was not observed until 3 days after the start of drug administration, after which depletion was rapid. After 5 days of treatment, the reduction was about 80% compared to pre-drug level. Serotonin restoration after drug withdrawal was very slow, and 5 days after discontinuation, it was still 70% below its baseline level.
Asunto(s)
Plaquetas/análisis , Imipramina/análogos & derivados , Antagonistas de la Serotonina/farmacología , Serotonina/sangre , Plaquetas/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Humanos , Imipramina/farmacología , MasculinoRESUMEN
The benzodiazepines are typified by a profile of side effects which includes drowsiness, ataxia and incoordination. Ro 15-1788, an imidazodiazepine derivative, exhibits marked antagonism of the behavioural and biochemical effects of the benzodiazepines in animals and man. It is devoid of any behavioural activity in animals, except at very high doses. In the present study the effects of single rising oral doses of Ro 15-1788 on cognitive, psychomotor and subjective function in man have been assessed using a battery of psychometric tests designed to identify the sedative action of the benzodiazepines. At all doses up to 600 mg, Ro 15-1788 demonstrated none of the classical behavioural effects of the benzodiazepines.
Asunto(s)
Benzodiazepinonas/farmacología , Encéfalo/efectos de los fármacos , Adulto , Cognición/efectos de los fármacos , Emociones/efectos de los fármacos , Fusión de Flicker/efectos de los fármacos , Flumazenil , Humanos , Masculino , Percepción/efectos de los fármacos , Psicometría , Tiempo de Reacción/efectos de los fármacosRESUMEN
In a double blind, placebo-controlled study the effects of daily oral administration of 3-cyano-imipramine on the 3H-serotonin uptake capacity of platelets were investigated in healthy volunteers. The initial dose was 1 mg, rising to 3 mg daily for 7 days. A rapid and profound inhibition of 3H-serotonin uptake was observed in platelets isolated from the treated subjects. During repeated administration, uptake was reduced to less than 10% of pre-drug values. Five days after the final dose uptake had only partially recovered, to 53% of pre-drug values. A similar inhibition profile was observed when serum from the treated subjects was incubated with normal platelets and 3H-serotonin. The results establish 3-cyano-imipramine as a potent inhibitor of platelet serotonin uptake in humans.
Asunto(s)
Plaquetas/metabolismo , Imipramina/análogos & derivados , Antagonistas de la Serotonina/farmacología , Serotonina/sangre , Adolescente , Adulto , Método Doble Ciego , Humanos , Imipramina/farmacología , MasculinoRESUMEN
Changes in platelet serotonin uptake and content were investigated following administration of a single oral dose of 3-cyano-imipramine to healthy volunteers. The uptake of 3H-serotonin by platelets harvested from these subjects was almost completely inhibited 4 h after dose administration. This inhibition continued for at least 24 h. Plasma taken from the subjects inhibited the uptake of 3H-serotonin by platelets isolated from non-treated subjects. A small but significant reduction in platelet serotonin content was observed 3.75 h after dosing and was still evident after 24 h.
Asunto(s)
Plaquetas/metabolismo , Imipramina/análogos & derivados , Serotonina/sangre , Administración Oral , Adolescente , Adulto , Plaquetas/análisis , Humanos , Imipramina/administración & dosificación , Imipramina/farmacología , Técnicas In Vitro , Masculino , Factores de TiempoRESUMEN
After intramuscular administration of 16 beta-ethyl-17 beta-hydroxy-4-4-[4-14C]estren-3-one (14C-oxendolone; 300 mg) to 3 human subjects, excretion of 14C was very slow and incomplete despite a 20-day sample collection period. During this time, means of 37% and 21% of the administered 14C were recovered in urine and faeces, respectively, and if excretion continued at the same rate, approximately 90% of the administered 14C would have been excreted during 5-12 weeks. Peak plasma 14C concentrations were reached at 3-6 days after dosing, when they represented 0.2-1.1 micrograms equiv./ml, and declined very slowly thereafter with a half-life of 5.0-6.6 days. Concentrations of unconjugated drug-related steroids circulating in plasma never exceeded about 0.1 microgram/ml. Mass spectroscopic analysis of isolated urinary and faecal metabolites indicated that the principal routes of biotransformation of oxendolone in man are similar to those of the endogenous androgens-namely, reduction of the 4,5-double bond, further reduction of the saturated 3-ketone to the 3 alpha-hydroxysteroid, and oxidation of the 17 beta-alcohol to the corresponding ketone, followed by conjugation, mainly with glucuronic acid, and excretion in the urine and bile.
Asunto(s)
Nandrolona/análogos & derivados , Adulto , Andrógenos/sangre , Biotransformación , Radioisótopos de Carbono , Cromatografía en Capa Delgada , Estradiol/sangre , Heces/análisis , Hormona Folículo Estimulante/sangre , Humanos , Inyecciones Intramusculares , Cinética , Hormona Luteinizante/sangre , Masculino , Nandrolona/administración & dosificación , Nandrolona/metabolismoRESUMEN
A group of young men volunteering for military service in the United States Navy were studied during an acute stress situation. The subjects (S's)(N = 62) were non-swimmers, and they all had to jump from a 5-foot platform into the deep end of a swimming pool. Before and after the exposure, blood and urine samples were taken for endocrine analysis. The Defense Mechanism Test (DMT), the Coping Operations Preference Enquiry (COPE), Joffe and Nanitch Scales for Defenses (J&N), and a Mood Questionnaire (MQ) were administered. For the endocrine reactions, postsamples, 3 factors emerged: a Cortisol factor, a Testosterone factor, and a Catecholamine factor. There was a significant correlation between the Cortisol factor and defense mechanisms, evaluated both by the DMT and the paper-and-pencil tests. Furthermore, there was a significant relationship between high anxiety, and defense mechanisms on the one hand, and physiological responses on the other.
Asunto(s)
Epinefrina/orina , Hidrocortisona/metabolismo , Norepinefrina/orina , Estrés Psicológico/metabolismo , Testosterona/sangre , Adaptación Psicológica/fisiología , Adulto , Ansiedad/metabolismo , Mecanismos de Defensa , Hormona del Crecimiento/sangre , Humanos , Masculino , Prolactina/sangre , Estrés Psicológico/psicología , NataciónRESUMEN
Falipamil (2-[3-[3-(3,4-dimethoxyphenetylmethylamino]propyl]-5,6- dimethoxyphthalamidine; 1) is a new specific bradycardic agent for the treatment of sinus tachycardia. Pharmacokinetics of falipamil in humans (n = 6) was determined in plasma and urine after iv administration of 100 mg (1.85 MBq) per person of 14C-labeled drug by liquid scintillation counting and by a specific, sensitive reversed-phase totally automated HPLC system with fluorimetric detection. Recovery of total radioactivity was 91.8 +/- 3.7%, with 68.2 +/- 4.3% in urine and 23.6 +/- 2.5% in the feces. The majority of radioactivity was excreted within 24 to 48 h. The parent drug, falipamil (1), and its N-desmethyl-metabolite (2), which is approximately 100 times less active than 1, contributed 14.1 +/- 1.6 and 4.5 +/- 0.7%, respectively, of the dose to urinary excretion. Plasma protein binding of 1 and 2 was 87.9 +/- 1.2 (concentration range: 2000-8000 ng/mL) and 89.7 +/- 0.5% (concentration range: 62.5-1000 ng/mL), respectively. Plasma concentrations of 1 peaked at 2 min at 724 +/- 173 ng/mL, declined biphasically, and were fitted to a two-compartment open model. Plasma concentrations of 2 were very low, in all cases ranging from 0 to 35 ng/mL. The dominant terminal half-life (beta-phase) of 1 from plasma was 1.8 +/- 0.6 h (range 1.4-2.9 h), mean residence time was 2.4 +/- 0.4 h, total body clearance was 1108.5 +/- 119 mL/min, and renal clearance was 117 +/- 20 mL/min. All parameters demonstrated very low intersubject variability.
Asunto(s)
Fármacos Cardiovasculares/farmacocinética , Ftalimidas/farmacocinética , Adulto , Fármacos Cardiovasculares/administración & dosificación , Humanos , Inyecciones Intravenosas , Isoindoles , Masculino , Ftalimidas/administración & dosificaciónRESUMEN
The bioavailability of isosorbide dinitrate from formulations containing 5, 10, and 20 mg in tablets and 10 mg in solution for oral use and 5 mg in tablets for sublingual use, has been compared. When adjusted for dose, the peak mean plasma drug concentrations after oral administration were similar (e.g., 9.2 ng/mL after a 10-mg tablet) and about one-half that obtained after sublingual administration. Drug concentrations declined monoexponentially with mean half-lives ranging from 25-36 min. The relative bioavailability of isosorbide dinitrate from the oral formulations was not significantly different (p greater than 0.05) over the dose range studied, whereas the relative bioavailability after sublingual administration was about twice as great (p less than 0.01) as that after oral administration. The plasma drug concentration-time profile after administering the 5-mg sublingual tablet was similar to that obtained after administering orally a solution containing 10 mg, indicating that the latter should be as clinically effective as the former.
Asunto(s)
Dinitrato de Isosorbide/sangre , Administración Oral , Adolescente , Adulto , Disponibilidad Biológica , Semivida , Humanos , Dinitrato de Isosorbide/administración & dosificación , MasculinoRESUMEN
Many investigations into schizophrenic speech dysfunction have not taken into account the mechanisms for normal speech production. Moreover, not all investigators have ensured that schizophrenic subjects belong to that group which does show deviant speech structures. We chose speech-disordered subjects who were asked to produce a narrative after viewing a short videostory. This provided a context in which to interpret even deviant narratives and in which to determine cohesive ties. It proved necessary to modify Rochester and Martin's categories of cohesive ties. No significant difference was found in the use of such ties overall. However, when examined category by category a pattern of different usage is evident, showing that schizophrenics suffer from a true dysfunction in narrative production.
Asunto(s)
Trastorno Bipolar/diagnóstico , Esquizofrenia/diagnóstico , Lenguaje del Esquizofrénico , Psicología del Esquizofrénico , Adulto , Atención , Trastorno Bipolar/psicología , Humanos , Psicolingüística , Semántica , Medición de la Producción del HablaRESUMEN
The synthetic oligopeptide pyroglutamyl-histidyl-prolyl-ß-alanine amide, structurally related to thyrotrophin releasing hormone (TRH), has been investigated in healthy male volunteers for its effect on pituitary thyroid function and on serum prolactin levels. In an open randomised 2-way crossover study the peptide has been compared with TRH on an equal dose basis following intravenous administration at 4 dose levels. The synthetic material had significantly lower thyrotrophin (TSH)-releasing activity than TRH while the prolactin releasing potencies of the 2 peptides were about equal.
RESUMEN
PIP: In women with preexisting virilization, it is advisable to prescribe contraceptive agents that do not provoke a further increase in free circulating androgens. This study evaluated the influence of 3 gestagens without androgenic effects on the endogenous sex hormone equilibrium and sex hormone-binding globulin (SHBG) concentrations. 122 women were administered 4 different combined contraceptives for up to 6 cycles. The estrogen component of each of the 4 preparations was estradiol estrogen (EE), while the gestagens were desogestrel (in 2 formulations in 2 different dosages), cyproterone acetate, and chlormadinone acetate. Most subjects had irregular cycles before treatment, and exhibited seborrhea, acne, and hirsutism. Luteinizing hormone, follicle-stimulating hormone, estrone, estradiol, progesterone, free testosterone, and dehydropeiandrosterone-sulfate levels were significantly reduced in all 4 treatment groups during tablet intake. However, SHBG concentrations increased in a highly significant manner during treatment. The elevation of SHBG is an expression of increased hepatic synthesis induced by EE. Concentrations of circulating SHBG determine the balance between estrogens and androgens. Since SHBG binds androgens better than estrogens, it effectively monitors androgenic activity. Because of their role in significantly lowering the active fraction of androgens, the preparations studied are considered appropriate contraceptives for androgenized women.^ieng
Asunto(s)
Anticonceptivos Orales Combinados/farmacología , Anticonceptivos Orales/farmacología , Hormonas Esteroides Gonadales/sangre , Gonadotropinas/sangre , Globulina de Unión a Hormona Sexual/metabolismo , Adulto , Femenino , HumanosRESUMEN
A randomized controlled study in a family practice setting was conducted on the use of hypnosis in helping people quit smoking. In the hypnosis group 21 percent of patients quit smoking by the three month follow-up compared with 6 percent in the control group. By six months there were no significant differences between the two groups, and at one year 22 percent in the hypnosis group and 20 percent in the control group had quit. The only significant predictor of success with quitting was having a college education.